Madrid, Spain – A thorough global analysis has uncovered a statistically notable association between Herpes Zoster vaccination – commonly known as the shingles vaccine – and a decreased risk of cardiovascular events, including heart attack and stroke.
The extensive study,representing the first systematic literature review and meta-analysis of its kind,examined data to determine the potential cardiovascular benefits of shingles vaccination.The findings were presented today at the 2025 European Society of Cardiology Congress.
Dr. Charles Williams,Global Associate Medical Director at GSK,stated that the research indicates a protective effect. “Our analysis suggests that vaccination against herpes zoster is linked to a lower incidence of cardiovascular events. While promising, these results necessitate further investigation to confirm a direct causal relationship,” Dr. Williams explained.
key Findings of the Global Analysis
Table of Contents
- 1. key Findings of the Global Analysis
- 2. Understanding Shingles and Cardiovascular Health
- 3. Frequently Asked Questions About Shingles and Heart Health
- 4. Is the cardiovascular benefit of the zoster vaccine linked to a reduction in systemic inflammation?
- 5. Zoster Vaccination Associated with Reduced Risk of Heart Attack and Stroke: Insights into Cardiovascular Benefits
- 6. The Unexpected Link Between Shingles and Heart Health
- 7. How Does the Zoster Vaccine Impact Cardiovascular Health?
- 8. Evidence from Recent Studies: Quantifying the risk Reduction
- 9. Who should Consider the Zoster Vaccine for Cardiovascular Protection?
- 10. Understanding the Different Zoster Vaccines
- 11. Practical Tips & Considerations
The study encompassed a review of 19 studies, including eight observational studies and a pooled safety analysis from Phase 3 randomized controlled trials. Results showed that both the recombinant herpes zoster vaccine (RZV) and the live attenuated zoster vaccine (ZVL) were associated with reduced cardiovascular risk in adults aged 18 and over, and also in those 50 and older.
Specifically, vaccination against shingles was associated with an 18% reduction in cardiovascular event risk for adults 18 and up, and a 16% reduction for those 50 and older. Across the studies, the research estimated between 1.2 to 2.2 fewer cardiovascular events per 1,000 person-years among vaccinated individuals.
| Vaccine Type | Risk Reduction (Adults 18+) | Risk Reduction (Adults 50+) | Absolute Risk Difference |
|---|---|---|---|
| RZV (Recombinant) | 18% | N/A | 1.2 – 2.2 events/1,000 person-years |
| ZVL (Live Attenuated) | 16% | N/A | 1.2 – 2.2 events/1,000 person-years |
Did You Know? Shingles affects approximately one in three individuals in their lifetime, and prior research has identified a temporary increase in heart attack and stroke risk following a shingles outbreak.
The analysis, conducted utilizing three major scientific literature databases, adhered to rigorous Cochrane guidelines for meta-analysis inclusion criteria. The majority of participants across the studies were male (53.3%), with average ages ranging from 53.6 to 74.0 years.
Dr. Williams cautioned that the majority of evidence originates from observational studies, which are susceptible to bias and cannot definitively prove causation. He also noted that the studies primarily focused on shingles prevention in the general population and may not fully reflect the effects on individuals with pre-existing cardiovascular risk factors.
herpes Zoster, or shingles, is triggered by the reactivation of the varicella-zoster virus (VZV) – the same virus responsible for chickenpox. After the initial chickenpox infection, the virus remains dormant in the nervous system and can reactivate, causing shingles. VZV can also affect both large and small blood vessels in the head, potentially causing inflammation and vascular changes that could lead to stroke.
Pro Tip: Consult with your healthcare provider to determine if shingles vaccination is appropriate for you, considering your age, health status, and potential cardiovascular risk factors.
Understanding Shingles and Cardiovascular Health
the link between shingles and cardiovascular events is a developing area of research.The VZV virus’s ability to impact blood vessels suggests a potential mechanism by which shingles – and perhaps vaccination against it – could influence heart health. Further research is crucial to unravel the complexities of this connection and to determine whether shingles vaccination should be considered as a preventative measure against cardiovascular disease.
Current recommendations from organizations like the Centers for Disease Control and Prevention (CDC) emphasize the importance of shingles vaccination for adults 50 and older, regardless of whether they have had shingles before. The vaccine is highly effective in preventing shingles and its complications,including postherpetic neuralgia (PHN),a long-term nerve pain condition.
Frequently Asked Questions About Shingles and Heart Health
- what is the connection between shingles vaccination and heart health? Research suggests a possible link between shingles vaccination and a lower risk of heart attack and stroke,though more study is needed to confirm a direct cause-and-effect relationship.
- Who should consider getting the shingles vaccine? The CDC recommends that healthy adults 50 years and older receive the shingles vaccine, regardless of whether they’ve had shingles previously.
- Are there different types of shingles vaccines? Yes,there are two available shingles vaccines: the recombinant zoster vaccine (RZV) and the live attenuated zoster vaccine (ZVL).
- Can shingles itself increase the risk of cardiovascular events? Previous research indicates a transient, temporary increase in heart attack and stroke risk following a shingles outbreak.
- What are the potential limitations of this new research? Most of the evidence comes from observational studies,meaning it cannot definitively prove that shingles vaccination *causes* a reduction in cardiovascular risk.
what are your thoughts on this new research? Share your comments below!
Is the cardiovascular benefit of the zoster vaccine linked to a reduction in systemic inflammation?
Zoster Vaccination Associated with Reduced Risk of Heart Attack and Stroke: Insights into Cardiovascular Benefits
The Unexpected Link Between Shingles and Heart Health
For years,the zoster vaccine – commonly known as the shingles vaccine – has been primarily recognized for preventing the painful rash associated with the reactivation of the varicella-zoster virus (the same virus that causes chickenpox). However,emerging research reveals a compelling connection between shingles vaccination and a substantially reduced risk of cardiovascular events,including heart attack and stroke. This article delves into the science behind this surprising link, exploring the mechanisms at play and offering guidance on zoster vaccine eligibility and benefits.
How Does the Zoster Vaccine Impact Cardiovascular Health?
The precise mechanisms aren’t fully understood,but several theories explain the observed cardiovascular benefits following Herpes zoster vaccination.
Inflammation Reduction: Shingles itself is characterized by important inflammation. The zoster vaccine appears to modulate the immune response, leading to a reduction in systemic inflammation. Chronic inflammation is a known driver of atherosclerosis – the buildup of plaque in arteries – increasing the risk of heart disease and stroke.
Endothelial Function Improvement: the endothelium,the inner lining of blood vessels,plays a crucial role in regulating blood flow and preventing clot formation. Studies suggest the shingles vaccine can improve endothelial function, contributing to better cardiovascular health.
Immune Rebalancing: The vaccine isn’t just about fighting the varicella-zoster virus; it seems to have a broader impact on the immune system,possibly correcting imbalances that contribute to cardiovascular disease. This immune response is key.
Vascular Protection: Research indicates a potential protective effect on blood vessels themselves,reducing the likelihood of damage and promoting overall vascular health.
Evidence from Recent Studies: Quantifying the risk Reduction
Several observational studies have demonstrated a clear association between zoster vaccination and reduced cardiovascular risk.
Large-Scale Population Studies: Analyses of health records from millions of individuals have consistently shown a lower incidence of heart attack and stroke in vaccinated individuals compared to those who remained unvaccinated.
Meta-Analyses: Combining data from multiple studies strengthens the evidence, revealing a statistically significant reduction in cardiovascular events – ranging from 15% to 30% – among those who received the shingles vaccine.
Specific Cardiovascular Conditions: Benefits have been observed across a range of cardiovascular conditions, including ischemic stroke, myocardial infarction (heart attack), and even peripheral artery disease.
Timeframe of Protection: The protective effects appear to be most pronounced within the first few years after vaccination, suggesting a rapid impact on cardiovascular risk factors.
Who should Consider the Zoster Vaccine for Cardiovascular Protection?
While the primary recommendation for shingles vaccination remains preventing the painful symptoms of shingles, the cardiovascular benefits add another compelling reason for eligible individuals to get vaccinated.
Age 50 and Older: The CDC recommends shingles vaccination for all adults aged 50 years and older, irrespective of whether they’ve had chickenpox. This is the population most at risk for both shingles and cardiovascular disease.
Individuals with Cardiovascular Risk Factors: People with existing heart disease, high blood pressure, high cholesterol, diabetes, or a family history of cardiovascular disease may particularly benefit from the added protection offered by the vaccine.
Immunocompromised Individuals: While the vaccine may be less effective in individuals with weakened immune systems, the potential benefits should be discussed with a healthcare provider.
Previous Shingles Infection: Even if you’ve already had shingles, vaccination is still recommended to prevent future occurrences and potentially reap the cardiovascular benefits.
Understanding the Different Zoster Vaccines
Currently, two shingles vaccines are available:
- Zostavax: A live-attenuated vaccine, no longer available in the US as of November 2020.
- Shingrix: A recombinant subunit vaccine,and the currently preferred option. Shingrix is more effective and provides longer-lasting protection than Zostavax. It’s administered in two doses, 2 to 6 months apart.
Shingrix is generally well-tolerated, with common side effects including pain, redness, and swelling at the injection site, as well as fatigue, headache, and muscle aches.These side effects are typically mild and resolve within a few days.
Practical Tips & Considerations
Talk to Your Doctor: Discuss your individual risk factors and whether the zoster vaccine is right for you.
Schedule Your Vaccination: Don’t delay! The sooner you’re vaccinated, the sooner you can benefit from the protection against both shingles and cardiovascular events.
Report Any Side Effects: If you experience any unusual or severe side effects after vaccination, contact your healthcare provider.
Maintain a Healthy Lifestyle: Vaccination is an significant step, but it
